Introduction
Defining a stem cell is simple in functional terms: a cell type capable of both self-renewal and differentiation ( Figure 1 ). Through the process of asymmetric division, a single division can result in the formation of both an identical stem cell and a more highly mature cell. Importantly, the outcome of HSC division is under strict physiologic control. During development, the absolute and relative number of stem cells increases, suggesting an emphasis on symmetric division favoring stem cell expansion. However, during adult tissue homeostasis, balanced asymmetric division results in sufficient self-renewal to sustain hematopoiesis throughout life and sufficient differentiation to produce mature cells necessary for blood. During times of physiologic stress such as hemorrhage, it is hypothesized that division may shift to more symmetric division favoring differentiation to replenish necessary mature cell pools.
In order to assure a persistent pool of regenerating cells without overgrowth of immature cell types, tight regulation of HSC division is required. Unchecked growth of immature hematopoietic cells is thought to represent a paradigm for malignant outgrowth, and is indeed the likely scenario for at least some cancers such as acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). 1 Whether it is a fundamental mechanism for all cancers remains to be seen, but identification of subsets of breast cancer cells that may be transferred to recipient animals and give rise to tumors has raised the possibility that stem cells may exist for many cancers. 2 Studying normal stem cell regulation may, therefore, be informative of pathways important to disordered self-renewal in malignancy.
The control of stem cell growth may have other implications for clinical care as well. The number of stem cells needed to rapidly achieve engraftment in a bone marrow (BM) transplant recipient is large and affects clinical care in two important settings. First, patient candidates for autografting in the setting of hematologic malignancy fail to yield sufficient numbers of cells to safely undergo this procedure in 10-20% of cases. 3 Second, the complexity of allograft matching precludes upwards of 30% of candidates for allogeneic transplantation. The presence of umbilical cord blood (CB) banks raises hope that the donor problem can be solved since these cells have substantial haplotype diversity. However, CB harvests typically lack sufficient quantities of stem cells to provide engraftment in an adult. Therefore, stem cell number is a significant constraint on two important therapeutic settings in oncology, and overcoming this limitation is a further compelling rationale for understanding stem cell regulation.
Deconstructing how stem cells work
Hematopoietic stem cell regulation is informed by four decades of research and represents the most highly understood area of stem cell biology. The approach to understanding stem cell regulation has, for the most part, been reductionistic. Following isolation of cells using physical, chemical, functional, or other characteristics, specific properties or pathways are investigated and inferences of regulatory relationships are made. Assessing such regulatory relationships has been enormously productive and has progressed in greatest extent as clear functional assays of hematopoiesis have been developed.
However, focusing exclusively on HSCs is clearly limited since stem cells exist within a complex microenvironment, responding to cues provided by their context. We and others have attempted to define some of the elements of the microenvironment, or niche, reasoning that the physiology governing this complicated system will likely involve complex interactions among multiple component parts (Figure 2) . The discussion to follow will sequentially deal with what has been learned about cell autonomous and nonautonomous features of stem cell regulation.
Cell cycle control
A characteristic shared among adult stem cells from many tissues is their relative quiescence. Stem cells generally have a slow rate of turnover while their descendent cells, often denoted as progenitor cells in the hematopoietic system or as 'transit' or 'amplifying' cells in other tissue types, are the drivers of largescale proliferation. It is these progenitor cells that provide the 10 billion blood cells per day necessary to simply maintain homeostasis. The relatively inactive cell cycling of stem cells has been hypothesized to be important in preserving this cell pool in times of stress, a hypothesis for which there is now experimental evidence. 4 What dictates the quiescence of stem cells is not known. Several exogenous influences have been proposed as well as intrinsic, or cell autonomous, mechanisms possibly determined by developmental state. Efforts to work outward from cell cycle controls to transmembrane receptors have provided insight into molecular switches governing quiescence and how manipulating them can alter stem cell numbers. Table 1 summarizes techniques for HSC expansion through direct and indirect manipulation and will be referred to throughout the text.
Cyclin-dependent kinase inhibitors
Cyclin-dependent kinase inhibitors (CDKIs) represent the most proximal mediators of cell quiescence, serving as checkpoints restricting transition through phases of the cell cycle. CDKIs are composed of two families, the Cip/Kip family including p21 Cip1/ Waf1 (hereafter referred to as p21), p27 Kip1 and p57 Kip2 and the Ink4 family including p16
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. 5 These subfamilies are distinguished by the specificity of the Global schema of HSC regulation. Cell autonomous regulators such as CDKIs and transcription factors are depicted with nonautonomous regulators such as cytokines, Notch ligands, Wnt, and others, which are provided by hematopoietic cells, adjacent bone marrow stroma, and distal sources. CLP, common lymphoid progenitor; CMP, common myeloid progenitor.
Regulation of hematopoietic stem cell growth EC Attar and DT Scadden cyclin-dependent kinase (CDKs) they inhibit. Cip/Kip members inhibit multiple cyclin-dependent kinases, with particular effect on CDK2. 6, 7 Ink4 members inhibit CDK4 and CDK6. 8, 9 CDKIs are generally regulated at a post-transcriptional level; however, p21 and, to a lesser extent, p27 are also under transcriptional control. [10] [11] [12] [13] [14] [15] [16] Assessing the relative expression of various transcription factors and cell cycle regulatory molecules in single HSCs, Cheng et al 17 determined that primitive, quiescent cells had markedly elevated levels of p21 compared with more differentiated progenitor cells.
To test the hypothesis that primitive HSCs are maintained in a state of quiescence by an inhibitory tone exerted by CDKIs, in vitro and in vivo analyses of hematopoietic stem and progenitor function have been carried out using BM from animals deficient in these molecules. These studies have demonstrated that BM of mice deficient for p21 have increased numbers of primitive HSCs and increased HSC cell cycling, 4 identifying p21 as a negative regulator of HSC proliferation. A similar function was identified for p27, but the effect was interestingly isolated to the more mature progenitor cell pool. 18 Additional studies of p16, p18, p57, and others are currently under investigation with preliminary data indicating distinct hematopoietic phenotypes for each of these cell cycle regulators.
Attempts have been made to expand HSCs ex vivo by posttranscriptional silencing of CDKIs. Lentiviral transduction of CD34 þ and CD34 þ 38 À cord blood cells with a full-length antisense to p21 resulted in a release of cell-cycle inhibition in quiescent cells and an increase in stem cells compared to mocktransduced cells as demonstrated by in vitro and in vivo assays. 19 Results with transient suppression of p21 using siRNA appear highly comparable. Similarly, antisense to p27, when combined with the pleiotropic growth factor TGF-b, has been utilized to release primitive hematopoietic cells from quiescence as a strategy to improve retroviral transduction efficiency. 101 While transient downregulation of these molecules may be desirable for stem cell expansion strategies, the potential for danger in long-term reduction is evident. Fortunately, neither loss of p21 nor p27 resulted in leukemia in mice and neither have been strongly implicated in human leukemia. 20 However, perturbations of p21 and p27 have been implicated in various malignancies including lung, colon, and breast cancer, underscoring potential similarities in self-renewal pathways among different tissue types and suggesting that manipulation efforts be made with caution. [21] [22] [23] [24] [25] Recent experience with RNAi, capable of causing transient reduction in gene expression, offers an attractive potential methodology.
Telomerase
Maintenance of telomere length is crucial to self-renewal, and many cancer cells activate telomerase to achieve this function and thereby subvert the endogenous limitation on division termed senescence. HSCs express high levels of telomerase 26 and telomere length has been observed to decrease with repeated transplantation. 27 Hematopoietic cells obtained from mice with targeted disruption of the telomerase reverse transcriptase (TERT) gene undergo premature exhaustion following serial transplantation. 28 Overexpression of TERT, however, does not confer increased stem cell self-renewal. 29 Transcription factor impact on stem cell self-renewal Once cells enter into cycle, they have several fate options: selfrenewal, differentiation or apoptosis. Influencing this 'choice' has obvious therapeutic and pathophysiologic implications, thereby driving considerable interest. Several recent studies have provided insight into the basis for these fate decisions, indicating key roles for transcriptional regulators such as homeodomain and polycomb genes.
Homeobox genes
Homeobox gene family members are differentially expressed during development and are central for overall body plan and 30 Conversely, enforced expression of HoxB4 in HSCs confers a heightened ability for in vivo stem cell function. 31, 32 In addition, ectopic expression of HoxB4 in embryonic stem (ES) cells combined with in vitro culture on stroma induces a switch to the definitive hematopoiesis phenotype transplantable into adult recipients, 33 thus establishing the possibility of stem cell therapy from ES cells.
In an effort to avoid possible deleterious effects of genetically manipulating HSCs, stromal cells have been engineered to secrete HoxB4 and therefore increase stem cell numbers ex vivo. In one example, stromal cells were modified to express HoxB4, which contained a signal peptide at the amino terminus to facilitate secretion. Hox proteins have the ability to passively diffuse across cell membranes and were therefore detected in adjacent HSCs. Cocultures of human CD34 þ CD38 lo cells on stromal cells secreting HoxB4 underwent a 20-fold increase in primitive cells as measured by the in vitro long-term culture initiating cell (LTC-IC) assay; they underwent a 2.5-fold increase as assessed by in vivo repopulation of severe combined immunodeficient mice (SCID). 34 Similar results have been observed when mouse BM was grown on stromal cells engineered to express HoxB4 preceded by the HIV transactivating protein (TAT). 35 HIV TAT is extremely efficient at passing across cell membranes and therefore coupling HoxB4 to TAT enhances intracellular delivery of HoxB4. Exposing cells to this chimeric protein in vitro resulted in a four-to six-fold increase in stem cells. 35 The magnitude of increase is encouraging and provides the promising possibility of finally achieving ex vivo stem cell expansion.
In addition, Pbx-1, a mammalian homologue of the extradenticle (Exd) homeodomain protein that functions as a cofactor for Hox transcription factors in Drosophila, has been found to have relevance to HSC self-renewal. While mice deficient for Pbx-1 experience embryonic lethality, Pbx-1 À/À fetal liver (FL) demonstrates reduced hematopoietic stem and progenitor cell activity relative to wt FL. 36 Numerous Hox relatives have been identified to act in breast and lung carcinogenesis and, in particular, AML. [37] [38] [39] [40] [41] In addition, Pbx-1 was identified by virtue of its disruption [t(1;19)] in a subset of pediatric leukemias. 42, 43 However, neither overexpression nor abrogation of HoxB4 expression has been has found to induce malignancy in hematopoietic cells. Therefore, techniques to manipulate this pathway for cell expansion by transient activation are being pursued.
Transcriptional repressors
Bmi-1 is a proto-oncogene and member of the Polycomb Group (PcG) that represents transcriptional repressors. Bmi-1 has been detected in both mouse and human HSCs and in leukemic stem cells. 44 The observation that Bmi-1 levels decline during hematopoietic development, and that Bmi-1 deficient mice develop hypocellular BM and die at less than 2 months of age, led to the suspicion that Bmi-1 is involved in maintenance of the HSC pool. Homozygous null animals have dramatic reductions in the numbers of HSCs as measured by immunophenotype and decreased capacity to repopulate all lineages following transplantation. At 8 weeks after transplantation, virtually no Bmi-1 À/À cells could be detected in recipients, suggesting a defect in stem cell self-renewal machinery required to replenish the stem cell pool. This impairment may be mediated via 16 Ink4a and/or p19 Arf , which are known to be suppressed by Bmi-1 and mediate cell cycle arrest or apoptosis, respectively.
Similarly, impaired repopulation was seen following transplantation of fetal liver cells obtained from mice deficient for Rae28, another member of the Polycomb complex 1, compared to wild-type animals. 45 Thus, manipulation of PcG members to alter stem cell self-renewal represents another unique targeting opportunity, particularly in the setting of malignant stem cells. 46 
Transcriptional co-activators
The Creb-binding protein (CBP) is a transcriptional regulator that acts both as a coactivator of transcription in association with a diverse set of transcription factors and by modifying chromatin through its histone acetyltransferase activity. 47, 48 In addition to other phenotypic abnormalities, CBP
þ /À mice demonstrate hematopoietic failure 49 and impaired HSC selfrenewal. 50 
Cell membrane molecules
The activities of various CDKIs and transcription regulators are modulated by cell membrane molecules, which play a role in transmitting signals from the extracellular environment into the cell. These may be broadly conceived as those that are among the cytokine and chemokine families (about which much is known in hematopoiesis) and those which are more recently appreciated such as morphogens and G-protein coupled receptors of the P2Y and frizzled families.
Cytokine growth factors
The ability to increase numbers of specific cellular populations using cytokines was first demonstrated in the 1980s. 51 Mouse BM was treated with 5-flourouracil (5-FU) to deplete cycling cells and then stimulated with conditioned media obtained from WEHI-3 cells. After 7 days of stimulation, a 60-fold increase in primitive progenitor cells (CFU-S 13 ) and a 53-fold increase in committed progenitor cells (GM-CFCs) were obtained. Subsequent studies by this and other groups demonstrated the ability to expand cells throughout the hematopoietic spectrum by the exogenous application of cytokines. [52] [53] [54] [55] These have culminated in the widespread use of hematopoietic colony-stimulating factors such as erythropoietin, granulocyte colony-stimulating factor (G-CSF), and granulocyte-monocyte stimulating factor (GM-CSF) in current clinical oncology practice. 56 Specific expansion of the stem cell pool has been achieved using combinations of cytokines, or cytokine cocktails, such as IL-11, Flt-3-ligand (Flt-3-L), and Steel factor 57, 58 and SCF, Tpo, and Flt-3-L with either IL-11 or IL-3. 59 However, cytokine-based strategies have limited utility in expansion of primitive HSCs for several reasons. The first is that HSCs are inherently unresponsive to cytokine stimulation. The second is that cytokines exert a pleiotropic effect on HSCs, often inducing differentiation rather than self-renewal and resulting in a heterogeneous population containing both primitive and differentiated cells. Thus, additional strategies to expand HSCs are clearly required.
Hedgehog, patched, smoothened and bone morphogenetic protein (BMP)
The Hedgehog (Hh) family of proteins is involved in the organization of early mesoderm and embryonic specification of nonhematopoietic tissues and may be generally categorized as morphogens. 60 Two candidate Hh transmembrane receptors Patched (Ptc) and Smoothened (Smo) were first identified in Drosophila, and Ptc is the primary Hh receptor. Human homologues of the Drosophila Hh are comprised of a family of three proteins, Sonic hedgehog (Shh), Indian hedgehog (Ihh) and Desert hedgehog (Dhh).
Hh molecules are expressed on the cell surface as transmembrane proteins and either bind directly to Ptc on adjacent cells or are cleaved and diffuse through the microenvironment to distal Ptc-expressing cells. Hh ligand binding results in Smo activation, with subsequent signaling events that modulate expression of such genes at Wnt-2a and a bone morphogenetic protein (BMP)-4-specific inhibitor, Noggin. 61, 62 BMP-4, a member of the transforming growth factor (TGF-b) superfamily, is expressed in ventral mesoderm and induces hematopoietic differentiation in Xenopus embryos. 63 BMPs are highly conserved and human homologues have been identified. While BMP-2 and -7 at high concentrations act similarly to TGFb and inhibit HSC proliferation, high levels of BMP-4 enhance stem cell survival. 64 Expression of Shh, Ptc, and Smo has been detected in primitive human HSCs. 65 Antibody to Hh blocked cytokineinduced proliferation of HSCs, while addition of soluble Shh resulted in increased stem cells as measured by nonobese diabetic-severe combined immunodeficency (NOD-SCID) mouse repopulating cell (SRC) assays. The mitogenic effect of Shh was inhibited by Noggin, demonstrating that Shh acts through BMP-4 in primitive blood cell proliferation. Therefore, there is clear intersection between the biochemical pathways of these morphogens in stem cells, suggesting an orderly relationship that can be targeted in drug development.
Both the Hh and BMP pathways have associations with malignancy. Hh has been implicated in pancreatic, gastrointestinal, and lung malignancies and is clearly identified as a dominant participant in basal cell carcinomas of the skin. [66] [67] [68] [69] [70] Manipulating these pathways for therapeutic advantage has been a daunting task, but early efforts, such as by using cyclopamine, a specific Hh pathway inhibitor, are encouraging.
Notch
The Notch receptor family is critical to HSC regulation, where it specifies stem cell fate at the decision of self-renewal vs differentiation, and to lymphopoiesis, where it specifies T-or Bcell differentiation from the common lymphoid progenitor and promotes expansion of CD8 þ T cells. 71 Following engagement with one of several extracellular ligands that include Delta and Jagged, Notch is cleaved and the intracellular portion translocates to the nucleus where it acts as a transcription factor on target genes.
Constitutive expression of the Notch intracellular domain may be used to establish immortalized cell lines from cytokinedependent hematopoietic stem cells, and these lines can reconstitute myeloid and lymphoid lineages in vivo and in vitro. [72] [73] [74] [75] Persistent activation of Notch is associated with lymphoid leukemia, a setting from which it was first identified in mammalian cells. 76 The complicated pleiotropism and oncogenicity of Notch raises concerns about activating this system therapeutically. Clearly, sustained activation is undesirable, but brief activation of Notch has resulted in substantial stem cell expansion in vivo and in vitro and use of this pathway in stem cell manipulation strategies has considerable appeal.
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G-protein coupled receptors
The identification of cell surface molecules preferentially expressed on primitive HSCs provides an opportunity for both detection and direct manipulation of this population. For example, primitive adult BM cells functionally isolated using cytokine stimulation and antimetabolite treatment were found to express high levels of the seven transmembrane (7-TM) Gprotein coupled receptor GPR105 or P2Y 14 . 78 Preferential expression of GPR105 was detected in approximately half of CD34 þ 38 -cells, and ectopic expression appears to shift cells to a more immature functional phenotype, impairing their differentiation. This receptor is a member of the purine/pyrimidine or P2Y receptor family and its ligand has been identified to be UDP-glucose. 79 That nucleotides and their conjugates may play a role in regulating mature tissue response to injury has been recognized for some time, 80 but the prospect that they are participants in governing a primitive population of regenerative cells is intriguing. This finding raises the interesting question of whether P2Y receptors may be an element of stem cell response to injury or, perhaps, excessive breakdown of abnormal cells in neoplastic states.
Another system involves the frizzled family of 7-TM receptors and their ligands, Wnts. Frizzled signals through a complex, well-characterized relay pathway containing the molecules disheveled, axin, APC, b-catenin, and others. In the nucleus, b-catenin releases TCF, which is a repressor of Wnt-target genes. 81 Transduction of primitive mouse c-Kit To show that the Wnt pathway is active in HSCs in vivo, HSCs were transduced with a construct containing a LEF-1/TCF reporter driving green fluorescence protein (GFP) and transplanted to irradiated animals. After 14 weeks, 28% of donor HSCs expressed GFP. Abrogation of Wnt signaling using a soluble form of the frizzled cysteine-rich domain, which blocks binding of Wnt proteins to the frizzled receptor, or by ectopically expressing axin, which induces b-catenin degradation, resulted in impaired HSC growth in vitro and in vivo. Increased levels of HoxB4 and Notch1 were found in HSCs transduced to express b-catenin, implying a role for these molecules in the observed phenotype. Lastly, direct application of purified Wnt-3a has been utilized to successfully expand HSCs. 83 These studies are extremely encouraging, providing basic insight and practical strategy for increasing stem cell numbers. Production of recombinant Wnt proteins, however, is technically very challenging and, therefore, full realization of this work in a clinical context may depend on identifying other means to activate the pathways involved.
Others
The glycosyl phosphatidylinositol-anchored protein (GPI-AP) Sca-1, used extensively to isolate murine HSCs, undergoes complex expression during hematopoiesis. Highly expressed on primitive cells, it is downregulated concurrently with differentiation and is then upregulated on specific progenitors. HSCs from Sca-1 null mice have impaired repopulation potential and self-renewal and undergo altered differentiation. 84 
Role of the stem cell niche
The ability of environmental cues to affect stem cell fate is a concept from embryology that has been extended to the adult organism with the notion that a highly specialized set of conditions exists to regulate the ultimate fate of anatomically restricted primitive cells. The physical interaction of stem cells with cells, matrix components and supportive factors is thought to define a 'niche' critical for the homeostatic maintenance of stem cell populations.
The experimental data to support the concept of a niche are derived largely from invertebrate animals. In elegant studies examining gonadal tissue of Drosophila and C. elegans, Spradling, Fuller, Schedl, Kimble and other investigators have demonstrated the critical need for a physical interaction of germ cell stem cells with supportive cells. [85] [86] [87] [88] [89] In some of these studies, it has been shown that sustained contact between stem cells with supportive 'Hub' cells was determinant of whether daughter cells retained a stem cell phenotype or undertook a differentiation program. Of relevance, in C. elegans, it has been shown that signaling via the Notch pathway directs gonadal stem cells to expand rather than undergo differentiation. 90 However, in vertebrate systems, the specific modular components of the niche and how they influence stem cell fate has not been well defined. The region where stem cells reside is known in skin, gut and brain, for example, but with which cells or molecular structures they interface is not known. Recent data have shed light on this issue in mammalian hematopoiesis.
Blood cell formation changes in location during development moving from extraembryonic regions to the aorto-gonadalmesonephros in the embryo and then to the liver in the first trimester. By the second trimester, BM, spleen and thymus become populated and eventually become the exclusive sites of hematopoiesis. With each change in location is an associated change in the production emphasis of the stem cell population, with stem cell expansion and erythropoiesis in great dominance early and a more balanced, full immune repertoire later. In addition, within the BM, differentiation exists in a gradient with more immature cells adjacent to bone and more mature cells adjacent to the endothelial lining of the sinus. Indeed, stem cells have been defined as residing within 6-10 cell diameters of the endosteal surface. 91 Therefore, location appears to participate in hematopoietic control and bone appears to provide something of importance for BM stem cells.
Two recent studies defined the BM osteoblast as a key participant in the hematopoietic stem cell niche. The first was achieved by a conditional knockout of the BMP1a receptor in the mouse. 92 In the absence of the receptor for this morphogen, bony and other morphologic abnormalities were observed. In association with increased trabecular bone, an increase in hematopoietic stem cells was noted. Further, physical interaction of the stem cells with the osteoblast was shown and colocalization of molecules such as N-cadherin was observed.
Undertaking a different approach, the role of the osteoblast was tested directly by examining the hematopoietic effects of a mouse transgenic for a constitutively active parathyroid hormone (PTH) receptor driven by an osteoblast specific promoter. 93 This mouse had increased trabecular bone in the metaphyses of long bones with an approximate four-fold increase in osteoblast numbers. The stem cell compartment (but, interestingly, not progenitors) was increased by about twofold, a comparable magnitude noted with the BMPR1a deficient mouse. This increase could be recapitulated in the normal mouse by use of exogenous PTH administration and could be achieved ex vivo by simple addition of PTH to stromal cultures. Of note, these changes were associated with increased production of the Notch ligand Jagged1 by osteoblasts, an increase in activated Notch in stem cells in vivo and abrogation of the effect by a gamma secretase inhibitor that blocks Notch activation. Therefore, the osteoblast was shown to be an important component of the stem cell niche and appeared to utilize the Notch pathway to increase stem cell numbers.
Two issues remained: does a two-fold change in stem cells matter and can this documentation of the osteoblast as a niche component have relevance to a clinical setting? To test these questions, a BM transplantation model was used, employing limiting numbers of stem cells, a context resembling what may be seen in humans with stem cell sources of limited number such as cord blood. In these experiments, PTH was administered beginning after the transplant and a marked difference was noted in the overall outcome. In the control animals, 73% died whereas in the PTH treated animals, none died (Po0.0001). BM histology of the PTH treated animals revealed markedly increased cellularity compared with controls. Therefore, there are meaningful effects that can be induced by PTH in settings mimicking a need in human medicine. One additional conclusion that can be drawn from these studies is that the niche can be a target for pharmacologic intervention that can result in a desirable stem cell outcome.
Future directions
The potential roles of specific genes implicated in HSC regulation have been determined by assaying hematopoietic cells from animals deficient for genes of interest. More recently, expression profiling strategies have been used to determine genetic and molecular signatures of HSCs and to determine possible similarities with stem cells of other tissue types. [94] [95] [96] [97] [98] Such genomic and proteomic techniques are technically limited by the low quantities of primitive cells available for analysis. Furthermore, while providing informative relative to the abundance of specific gene transcripts and proteins, they lack information about signaling pathways and interactions that guide cell outcomes. Nonetheless, applying such global approaches to both stem cells and their niche promises to help identify novel biologic processes that can be targeted and pathways that can be manipulated for therapeutic gain.
Concluding remarks
Studies on hematopoietic stem cell regulation are beginning to define specific targets either intrinsic to the stem cell or to the microenvironment that can be manipulated to produce changes highly relevant to clinical settings. Much of this work has been discovered using mouse models and active translation to the human setting needs to be aggressively pursued. However, the advent of new approaches to manipulating stem cells is likely to alter the outlook for gene therapy and stem cell transplantation in the immediate future. More intriguing long-term possibilities reside in the parallels that can be drawn between cancer and stem cell biology. The molecular biology of cell cycle regulation has been elucidated in cancer and is now being applied to stem cells. In turn, it is hoped that defining the processes of self-renewal and differentiation and the role of the microenvironment in the stem cell will result in new approaches to understand and treat cancer.
